VBI-1901 is a novel immunotherapy developed using VBI’s eVLP technology On track to initiate a Phase 1/2a clinical study in the second half of 2017 VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious...
Read More
Well tolerated at all doses with no safety signals 100% seroconversion at highest dose after two of the three planned vaccinations Dose-dependent antibody responses against CMV gB antigen Full data after third dose expected first half of 2018 Conference Call...
Read More
Replay Webcast VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) announced today its plans for a global Phase 3 clinical program for Sci-B-Vac™, its third-generation hepatitis B vaccine, following positive discussions with the U.S. Food & Drug Administration (FDA), the...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today announced the voting results from its annual general and special meeting (the “Meeting”) held on June 22, 2017. 30,823,557 common shares were represented at the Meeting, totaling 76.94% of VBI issued and...
Read More
VBI Vaccines, Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has been added to the Russell 2000® and the Russell 3000® Indexes following the annual reconstitution, which...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has completed a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, VBI’s President and CEO, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today provided an update on its cytomegalovirus (“CMV”) Phase I clinical study, which is assessing the safety and tolerability of VBI’s vaccine candidate to prevent congenital CMV infection. Congenital CMV infection is...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present updates on two of its programs at the World Vaccine Congress on Tuesday, April 11, 2017 at 3:40 PM ET and 4:40 PM ET. The event is being...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) and SciVac Ltd. (“SciVac”), a wholly owned subsidiary of VBI, are pleased to announce the appointment of Avi Mazaltov as the Global Head of Manufacturing and General Manager of the SciVac manufacturing...
Read More